Moses Braimoh
Public Health & General Preventive Medicine · Lafayette, LANPI 1467984146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Viiv Healthcare Company at 36.1% of the total. 2025 is the largest year on record at $2,723, more than ten times the $237 reported in 2023.
Across 199 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Merck$337
- Braeburn Inc.$258
- Alkermes, Inc.$255
- Theratechnologies Inc.$225
- plus $499 from 9 others
What the payments were for
- Food & beverage$4,216100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 68 | $1,524 |
| Gilead | 61 | $1,118 |
| Merck | 16 | $337 |
| Braeburn Inc. | 17 | $258 |
| Alkermes, Inc. | 10 | $255 |
| Theratechnologies Inc. | 7 | $225 |
| Otsuka America Pharmaceutical, Inc. | 7 | $133 |
| Novo Nordisk | 1 | $105 |
| EMD Serono, Inc. | 3 | $79 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| AbbVie | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Exact Sciences | 1 | $21 |
| Johnson & Johnson | 1 | $14 |
| Indivior Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few public health & general preventive medicine providers in Louisianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrogarzoIbalizumab-Uiyk | 23 | $142,765 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $78,045 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $30,293 |
| Gabapentin | 14 | $231 |
| Sodium Chloride0.9 % Sodium Chloride | 22 | $57 |
| Losartan Potassium | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Theratechnologies Inc.Trogarzo | $225 | $142,76523 claims |
| GileadBiktarvy, Descovy | $1,118 | $108,33829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few public health & general preventive medicine providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other public health & general preventive medicine in Lafayette
- Juliette StefanskiLafayette$76
- Saman JayasingheNew Orleans$2K
- Steven BuddNew Orleans$456
- Keith BlackmanRiver Ridge$268
- Raoult RatardMetairie$107
- Frank WelchMetairie$13
- William RigginsThibodaux$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.